ArticleTranslational cancer research2022
Risk factors for lower extremity lymphedema after cervical cancer treatment: a systematic review and meta-analysis.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Risk factors for lower limb lymphedema after gynecological cancer treatment: a systematic review.Frontiers in oncology · 2025Pooled it
- Natural History of Subclinical Lower Limb Lymphedema After Gynecologic Cancer Surgery Using Indocyanine Green Lymphography.Plastic and reconstructive surgery. Global open · 2026Article
- Characterizing trimodal therapy outcomes by HIV status in early-stage cervical cancer: a retrospective cohort study from a Kenyan tertiary centre.BMC cancer · 2026Article
- Lower extremity lymphedema after pelvic nodal dissection for urologic cancers is associated with metastatic recurrence.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Lower extremity lymphedema in patients with gynecologic cancer: Validation of the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) in German language and investigation of lymphedema real-world treatment.Archives of gynecology and obstetrics · 2025Observational
- Unilateral lower extremity lymphedema followed by COVID-19 vaccination in patients with cervical cancer history: two case reports.Journal of Yeungnam medical science · 2025Article
- Post treatment lower limb lymphedema in carcinoma cervix.Ecancermedicalscience · 2025Article
- Analysis of Risk Factors of Lymphedema After Surgical Treatment in Cervical Cancer: A Case-Control Retrospective Study.International journal of general medicine · 2025Article
- Construction of a nomogram for personalized prediction of lower limb lymphedema risk after cervical cancer surgery.BMC women's health · 2024Article
- Computer-aided diagnosis for screening of lower extremity lymphedema in pelvic computed tomography images using deep learning.Scientific reports · 2023Article
- A Review of Advanced Multifunctional Magnetic Nanostructures for Cancer Diagnosis and Therapy Integrated into an Artificial Intelligence Approach.Pharmaceutics · 2023Review
- Single and combined impacts of irradiation and surgery on lymphatic vasculature and fibrosis associated to secondary lymphedema.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment. Methods: We searched the English database PubMed, Embase, Medline, Central and the Chinese database CNKI to obtain relevant studies. Inclusion criteria: (I) the subjects were cervical cancer patients receiving treatment; (II) cohort studies or case-control studies; (III) exposure factors were not limited; (IV) the outcome was lower extremity lymphedema after treatment; (V) the odds ratio (OR) value and 95% confidence interval of exposure factors can be obtained. The chi-square test was used to test for heterogeneity. The Egger test was used to test for publication bias. OR (95% CI) was calculated using inverse variance. Results: A total of 12 retrospective studies with a total of 3,401 patients were included in this literature review. The incidence of lower extremity lymphedema after cervical cancer treatment was between 12.6% and 43.1%. Meta-analysis results demonstrated that the main risk factors were: body mass index (BMI) (OR =1.37, 95% CI: 1.10-1.71, P=0.005), age (OR =1.68, 95% CI: 1.07-2.64, P=0.02), International Federation of Gynecology and Obstetrics (FIGO) stage (OR =1.50, 95% CI: 1.24-1.82, P<0.001), radiotherapy (OR =2.87, 95% CI: 1.71-4.82, P<0.001), lymph node (LN) dissection (OR =3.24, 95% CI: 1.44-7.31, P=0.005), and the number of LNs dissected (OR =2.34, 95% CI: 1.80-3.05, P<0.001). Egger's test showed that there was no publication bias among the literatures (P>0.05). Conclusions: BMI, age, FIGO stage, radiotherapy, LN dissection and the number of LNs removed are the main risk factors for lower extremity lymphedema after cervical cancer treatment. When treating patients with cervical cancer, effective interventions should be sought to reduce the risk of lower extremity edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.